Biology of recently discovered cytokines: Interleukin-17 - A unique inflammatory cytokine with roles in bone biology and arthritis

Arthritis Research and Therapy

Volumn 6, Issue 6, 2004, Pages 240-247

  Gaffen, Sarah L ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Bone; Cytokines; Inflammation; Interleukin 17; Synergy

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; TUMOR NECROSIS FACTOR ALPHA;

AMINO ACID SEQUENCE; BONE METABOLISM; BONE TURNOVER; CARCINOGENESIS; CHROMOSOME 6; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; GENETIC CODE; GENETIC TRANSCRIPTION; HOMEOSTASIS; HUMAN; IMMUNE SYSTEM; MOLECULAR MECHANICS; NONHUMAN; OSTEOLYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; STOICHIOMETRY; T LYMPHOCYTE;

ANIMALS; ARTHRITIS, RHEUMATOID; BONE DISEASES; BONE REMODELING; CYTOKINES; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; IMMUNITY, NATURAL; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-17; MICE; MICE, KNOCKOUT; MULTIGENE FAMILY; OSTEOARTHRITIS; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-17; SIGNAL TRANSDUCTION; VERTEBRATES;

EID: 8544277272     PISSN: 14786354     EISSN: None     Source Type: Journal    
DOI: 10.1186/ar1444     Document Type: Review

References (86)

1. Rouvier E, Luciani M-F, Mattei M-G, Denizot F, Golstein P: CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a Herpesvirus Saimiri gene. J Immunol 1993, 150:5445-5456.
2. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, Pin J-J, Garrone P, Garcia E, Saeland S, et al.: T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996, 183:2593-2603.
3. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ: Cutting Edge: Human IL-17: A novel cytokine derived from T cells. J Immunol 1995, 155:5483-5486.
4. Yao Z, Spriggs MK, Derry JMJ, Strockbine L, Park LS, VandenBos T, Zappone J, Painter SL, Armitage RJ: Molecular characterization of the human interleukin-17 receptor. Cytokine 1997, 9: 794-800.
5. Tsang M, Friesel R, Kudoh T, Dawid IB: Identification of Sef, a novel modulator of FGF signalling. Nat Cell Biol 2002, 4:165-169.
6. Yang RB, Ng CK, Wasserman SM, Komuves LG, Gerritsen ME, Topper JN: A novel interleukin-17 receptor-like protein identified in human umbilical vein endothelial cells antagonizes basic fibroblast growth factor-induced signaling. J Biol Chem 2003, 278: 3232-33238.
7. Xiong S, Zhao Q, Rong Z, Huang G, Huang Y, Chen P, Zhang S, Liu L, Chang Z: hSef inhibits PC-12 cell differentiation by interfering with Ras-mitogen-activated protein kinase MAPK signaling. J Biol Chem 2003, 278:50273-50282.
8. Aggarwal S, Gurney AL: IL-17: A prototype member of an emerging cytokine family. J Leukoc Biol 2002, 71:1-8.
9. Eberl M: Don't count your interleukins before they've hatched. Trends Immunol 2002, 23:341-342.
10. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, Maruoka M, Mao W, Foster J, Kelley RF, et al.: IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001, 20: 332-5341.
11. Shi Y, Ullrich SJ, Zhang J, Connolly K, Grzegorzewski KJ, Barber MC, Wang W, Wathen K, Hodge V, Fisher CL, et al.: A novel cytokine receptor-ligand pair. Identification, molecular characterization, and in vivo immunomodulatory activity. J Biol Chem 2000, 275:19167-19176.
12. Yao Z, Fanslow WC, Seldin MF, Rousseau A-M, Painter SL, Comeau MR, Cohen JI, Spriggs MK: Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995, 3:811-821.
13. + T cells by cyclic AMP-dependent signal transduction pathway. Cytokine 1998, 10: 41-850.
14. Shin HC, Benbernou N, Esnault S, Guenounou M: Expression of IL-17 in human memory CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine 1999, 11:257-266.
15. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD: Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998, 111:645-649.
16. Aarvak T, Chabaud M, Miossec P, Natvig JB: IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J Immunol 1999, 162:1246-1251.
17. Chabaud M, Page G, Miossec P: Enhancing effect of IL-1, IL-17, and TNF-alpha on macrophage inflammatory protein-3alpha production in rheumatoid arthritis: regulation by soluble receptors and Th2 cytokines. J Immunol 2001, 167:6015-6020.
18. Albanesi C, Cavani A, Girolomoni G: IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes: synergistic or antagonistic effects with IFN-γ and TNF-α. J Immunol 1999, 162: 94-502.
19. Infante-Duarte C, Horton HF, Byrne MC, Kamradt T: Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000, 165:6107-6115.
20. Happel KI, Zheng M, Young E, Quinton LJ, Lockhart E, Ramsay AJ, Shellito JE, Schurr JR, Bagby GJ, Nelson S, et al.: Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-1 7 expression in response to Klebsielia pneumoniae infection. J Immunol 2003, 170:4432-4436.
21. Aggarwal S, Ghilardi N, Xie MH, De Sauvage FJ, Gurney AL: Interleukin 23 promotes a distinct CD4 T cell activation state characterized by the production of interieukin 17. J Biol Chem 2003, 278:1910-1914.
22. Ghilardi N, Kljavin N, Chen Q, Lucas S, Gurney A, de Sauvage FJ: Compromised humoral and delayed-type hypersensitivity responses in IL-23-deficient mice. J Immunol 2004, 172:2827-2833.
23. Ziolkowska M, Koc A, Luszczukiewicz G, Ksiezopolksa-Pietrzak K, Klimczak E, Chwalinska-Sadowska H, Maslinski W: High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J Immunol 2000, 164:2832-2838.
24. Moseley TA, Haudenschild DR, Rose L, Reddi AH: Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003, 14:155-174.
25. Liu X, Lin X, Gaffen SL: Crucial role for nuclear factor of activated T cells (NFAT) in T cell receptor-mediated regulation of the human interleukin-17 gene. J Biol Chem 2004, Sep 30 [Epub ahead of print]
26. Sheridan CM, Heist EK, Beals CR, Crabtree GR, Gardner P: Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3. J Biol Chem 2002, 277:48664-48676.
27. Yao Z, Timour M, Painter S, Fanslow W, Spriggs M: Complete nucleotide sequence of the mouse CTLA8 gene. Gene 1996, 168: 23-225.
28. Lindsten T, June CH, Ledbetter JA, Stella G, Thompson CB: Regulation of lymphokine messenger RNA stability by a surface-mediated T-cell activation pathway. Science 1989, 244: 339-343.
29. Miossec P: Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy. Arthritis Rheum 2003, 48:594-601.
30. Laan M, Cui A-H, Hoshino H, Lötvall J, Sjöstrand M, Gruenert DC, Skoogh B-E, Lindén A: Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J Immunol 1999, 162:2347-2352.
31. Maertzdorf J, Osterhaus AD, Verjans GM: IL-17 expression in human herpetic stromal keratitis: modulatory effects on chemokine production by corneal fibroblasts. J Immunol 2002, 169: 897-5903.
32. Van Bezooijen RL, Papapoulos SE, Lowik CW: Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling? Bone 2001, 28:378-386.
33. Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, Polubinska A, Friess H, Gahl GM, Frei U, et al.: IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol 2000, 165:5814-5821.
34. Ruddy MJ, Shen F, Smith J, Sharma A, Gaffen SL: Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: Implications for inflammation and neutrophil recruitment. J Leukoc Biol 2004, 76:135-144.
35. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, Gaffen SL: Functional cooperation between interleukin-17 and tumor necrosis factor-α is mediated by CCAAT/enhancer binding protein family members. J Biol Chem 2004, 279:2559-2567.
36. Woltman AM, de Haij S, Boonstra JG, Gobin SJ, Daha MR, van Kooten C: Interleukin-17 and CD40-ligand synergistically enhance cytokine and chemokine production by renal epithelial cells. J Am Soc Nephrol 2000, 11:2044-2055.
37. Takaya H, Andoh A, Makino J, Shimada M, Tasaki K, Araki Y, Bamba S, Hata K, Fujiyama Y, Bamba T: Interleukin-17 stimulates chemokine (interleukin-8 and monocyte chemoattractant protein-1) secretion in human pancreatic periacinar myofibroblasts. Scand J Gastroenterol 2002, 37:239-245.
38. Eickelberg O, Pansky A, Mussmann R, Bihl M, Tamm M, Hildebrand P, Perruchoud AP, Roth M: Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. J Biol Chem 1999, 274:12933-12938.
39. Tokuda H, Kanno Y, Ishisaki A, Takenaka M, Harada A, Kozawa O: Interleukin (IL)-17 enhances tumor necrosis factor-alpha-stimulated IL-6 synthesis via p38 mitogen-activated protein kinase in osteoblasts. J Cell Biochem 2004, 91:1053-1061.
40. Baker P: The role of immune responses in bone loss during periodontal disease. Microbes Infect 2000, 2:1181-1192.
41. Theill L, Boyle W, Penninger J: RANK-L and RANK: T cells, bone loss and mammalian evolution. Annu Rev Immunol 2002, 20: 795-823.
42. Ducy P, Schinke T, Karsenty G: The osteoblast: a sophisticated fibroblast under central surveillance. Science 2000, 289:1501-1504.
43. Teitelbaum S: Bone resorption by osteoclasts. Science 2000, 289:1504-1508.
44. Rodan GA, Martin TJ: Therapeutic approaches to bone diseases. Science 2000, 289:1508-1514.
45. Nakashima T, Wada T, Penninger JM: RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol 2003, 15:280-287.
46. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al.: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
47. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli S, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, et al.: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397:315-323.
48. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, McCabe S, Elliott R, Scully S, Van G, et al.: RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci USA 2000, 97:1566-1571.
49. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al.: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997, 89:309-319.
50. Grcevic D, Katavic V, Lukic IK, Kovacic N, Lorenzo JA, Marusic A: Cellular and molecular interactions between immune system and bone. Croat Med J 2001, 42:384-392.
51. Kong Y-Y, Gelge U, Sarosi H, Bolon B, Tafuri A, Morony S, Cappareli C, Li J, Elliott R, McCabe S, et al.: Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999, 402:304-309.
52. Nakashima T, Kobayashi Y, Yamasaki S, Kawakami A, Eguchi K, Sasaki H, Sakai H: Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000, 275:768-775.
53. Choy EH, Panayi GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001, 344: 07-916.
54. van Bezooijen RL, Farih-Sips HCM, Papapoulos SE, Löwik CWGM: Interleukin-17: a new bone acting cytokine in vitro. J Bone Miner Res 1999, 14:1513-1521.
55. Johnson RB, Wood N, Serio FG: Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol 2004, 75:37-43.
56. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, Miossec P: Human interleukin 17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.
57. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, Schwarzenberger P, Coenen-de Roo CJ, Kolls JK, Joosten LA, van den Berg WB: IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003, 170: 655-2662.
58. Nakae S, Nambu A, Sudo K, Iwakura Y: Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
59. Lubberts E, Joosten LAB, Chabaud M, van den Bersselaar L, Oppers B, Coenen-de Roo CJJ, Richards CD, Miossec P, van den Berg WB: IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion. J Clin Invest 2000, 105:1697-1710.
60. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, Joosten LA, van den Berg WB: Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50: 50-659.
61. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P: IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res 2001, 3:168-177.
62. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, Schwarzenberger P, van de Loo FA, van den Berg WB: IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
63. Lubberts E, Joosten LA, van de Loo FA, Schwarzenberger P, Kolls J, van den Berg WB: Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm Res 2002, 51: 102-104.
64. Lubberts E, Joosten LA, van de Loo FA, van den Gersselaar LA, van den Berg WB: Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum 2000, 43: 1300-1306.
65. Nurieva RI, Treuting P, Duong J, Flavell RA, Dong C: Inducible costimulator is essential for collagen-induced arthritis. J Clin Invest 2003, 111:701-706.
66. McCauley LK: Transgenic mouse models of metabolic bone disease. Curr Opin Rheumatol 2001, 13:316-325.
67. Jilka RL, Hangoc G, Girasole G, Passeri G, Williams DC, Abrams JS, Boyce B, Broxmeyer H, Manolagas S: Increased osteoclast development after estrogen loss: mediated by interleukin-6. Science 1992, 257:88-91.
68. Baker PJ, Dixon M, Evans RT, Dufour L, Johnson E, Roopenian DC: CD4+ T cells and the proinflammatory cytokines gamma interferon and interleukin-6 contribute to alveolar bone loss in mice. Infect Immun 1999, 67:2804-2809.
69. Page R, Kornman K (editors): Periodontology 2000. Copenhagen: Munksgaard; 1997.
70. Kantarci A, Oyaizu K, Van Dyke TE: Neutrophil-mediated tissue injury in periodontal disease pathogenesis: findings from localized aggressive periodontitis. J Periodontol 2003, 74: 6-75.
71. Baker PJ, DuFour L, Dixon M, Roopenian DC: Adhesion molecule deficiencies increase Porphyromonas gingivalis-induced alveolar bone loss in mice. Infect Immun 2000, 68: 103-3107.
72. Knappe A, Hiller C, Niphuis H, Fossiez F, Thurau M, Wittmann S, Kuhn EM, Lebecque S, Banchereau J, Rosenwirth B, et al.: The interleukin-17 gene of herpesvirus saimiri. J Virol 1998, 72: 5797-5801.
73. Patera AC, Pesnicak L, Bertin J, Cohen JI: Interleukin 17 modulates the immune response to vaccinia virus infection. Virology 2002, 299:56-63.
74. Tartour E, Fossiez F, Joyeux I, Galinha A, Gey A, Claret E, Sastre-Garau X, Couturier J, Mosseri V, Vives V, et al.: Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res 1999, 59: 698-3704.
75. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, Fridman WH, Tartour E: Interleukin-17 inhibits tumor cell growth by means of a T-cell- dependent mechanism. Blood 2002, 99:2114-2121.
76. Luzza F, Parrello T, Monteleone G, Sebkova L, Romano M, Zarrilli R, Imeneo M, Pallone F: Up-regulation of IL-17 is associated with bioactive IL-8 expression in Helicobacter pylori-infected human gastric mucosa. J Immunol 2000, 165:5332-5337.
77. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, Oliver P, Huang W, Zhang P, Zhang J, et al.: Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001, 194: 19-527.
78. Linden A, Adachi M: Neutrophilic airway inflammation and IL-17. Allergy 2002, 57:769-775.
79. Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske A, Nelson S, Bagby GJ, Stoltz S, Mynatt RL, et al.: IL-17 stimulates granulopoiesis in mice: Use of an alternate, novel gene therapy-derived method for in vivo evaluation of cytokines. J Immunol 1998, 161:6383-6389.
80. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, Sekikawa K, Asano M, Iwakura Y: Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002, 17:375-387.
81. Pan G, French D, Mao W, Maruoka M, Risser P, Lee J, Foster J, Aggarwal S, Nicholes K, Guillet S, et al.: Forced expression of murine IL-17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan inflammation in mice. J Immunol 2001, 167:6559-6567.
82. Ozaki K, Leonard WJ: Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem 2002, 277: 9355-29358.
83. Pullen SS, Dang TT, Crute JJ, Kehry MR: CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding site specificity and activation of downstream pathways by distinct TRAFs. J Biol Chem 1999, 274:14246-14254.
84. Schwandner R, Yamaguchi K, Cao Z: Requirement of tumor necrosis factor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med 2000, 191:1233-1239.
85. Akira S: Toll-like receptors and innate immunity. Adv Immunol 2001, 78:1-56.
86. Faour WH, Mancini A, He QW, Di Battista JA: T-cell-derived interleukin-17 regulates the level and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of the p38 mitogen-activated protein kinase cascade: role of distal sequences in the 3′ -untranslated region of COX-2 mRNA. J Biol Chem 2003, 278:26897-26907.